COVID-19 in clinical practice: A narrative synthesis

Area of Science:

• Virology
• Epidemiology
• Public Health

Background:

• The emergence and rapid global spread of COVID-19, caused by SARS-CoV-2, a novel betacoronavirus.
• The primary mode of transmission is through respiratory droplets, targeting the ACE-2 receptor.
• As of July 26, 2020, over 15.2 million cases and 650,000 deaths were reported worldwide.

Purpose of the Study:

• To summarize the epidemiological characteristics and clinical presentation of COVID-19.
• To review the current therapeutic landscape for COVID-19.
• To highlight the potential of immunomodulatory treatments.

Main Methods:

• Review of reported COVID-19 cases and mortality data.
• Analysis of transmission dynamics and clinical symptoms.
• Evaluation of existing and emerging treatment strategies.

Main Results:

• COVID-19 exhibits a wide mortality rate (1.3-18.3%) and a high reproductive rate (4-5.1 in France without intervention).
• Respiratory symptoms, including fever and acute respiratory failure, are predominant in hospitalized patients.
• No antiviral therapies have demonstrated efficacy in randomized trials to date.

Conclusions:

• Corticosteroids, an immunomodulatory treatment, have shown significant improvements in patient outcomes.
• Further research into effective antiviral therapies is crucial.
• Public health interventions remain critical in managing the pandemic.